Stock · PFE · Healthcare
United States · Large Cap · listed since 1942 · Revenue 12 mo. $63.6B
Price as of 11/06/2026
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Original text from the data provider
Summary
51.3 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €8.1B (2025), it supports €90.5B. The remaining €64.4B of the market value assume it grows 7.6% a year for 10 years and not at all afterwards.
Required FCF growth per year
7.6%
no growth afterwards
Price to operating cash flow 11.9×, within its usual range.
Middle half of 20 quarters: 10.0× to 14.5×, median 11.4×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q2 → Q3 2026
5 more unchanged: Revenue, 12 mo., Gross margin, Net debt, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 8.99% | 11.52% | Rank 38 |
| Return on capital (Greenblatt) | 63.43% | 32.55% | Rank 78 |
| EBIT margin | 27.82% | 18.31% | Rank 79 |
| FCF margin | 14.50% | 14.12% | Rank 53 |
| Gross margin | 74.33% | 60.99% | Rank 78 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | −1.65% | 8.04% | Rank 8 |
| Earnings growth, 3 years per year | −37.02% | 5.44% | Rank 4 |
| Earnings growth, 5 years per year | −3.42% | 7.00% | Rank 24 |
| Sustainable growth (ROE × retained earnings) | 4.20% | 3.66% | Rank 55 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 4.65% | 2.90% | Rank 77 |
| FCF yield | 5.26% | 3.63% | Rank 75 |
| EV/saleslower is better | 3.62 | 4.03 | Rank 53 |
| EV/EBITlower is better | 13.01 | 21.73 | Rank 83 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 8.66% | 8.66% | Rank 50 |
| Share price, 6 months | 14.93% | 24.27% | Rank 38 |
| Share price, 3 months | 14.96% | 15.42% | Rank 48 |
| Distance from 52-week high | −4.55% | −7.35% | Rank 62 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −1.23% | 0.30% | Rank 65 |
| Change in share countlower is better | −0.25% | 0.00% | Rank 55 |
| Dividend streak in years | 16 | 10 | Rank 76 |
| Price reaction to results, market-adjusted | −2.25% | 0.05% | Rank 25 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 41.54% | 48.40% | Rank 36 |
| Net debt/EBITDAlower is better | 3.21 | 1.11 | Rank 13 |
| Debt to equitylower is better | 0.78 | 0.48 | Rank 30 |
| Volatility, 1 yearlower is better | 22.09% | 31.42% | Rank 98 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 52.8 | 26.0% | 13.9 | 1.23B | 39.5 |
| 2017 | 52.5 | 26.8% | 14.3 | 1.21B | 41.3 |
| 2018 | 40.8 | 16.5% | 13.6 | 5.98B | 40.1 |
| 2019 | 40.9 | 17.9% | 10.0 | 5.68B | 50.8 |
| 2020 | 41.7 | 21.2% | 11.6 | 5.63B | 36.5 |
| 2021 | 81.3 | 24.9% | 29.9 | 5.71B | 35.1 |
| 2022 | 101.2 | 37.7% | 26.0 | 5.73B | 34.5 |
| 2023 | 59.6 | 7.4% | 4.8 | 5.71B | 72.2 |
| 2024 | 63.6 | 23.5% | 9.8 | 5.70B | 66.0 |
| 2025 | 62.6 | 27.8% | 9.1 | 5.69B | 66.3 |
3 of 7 StockScorer Score rules met · How the score is built
Pfizer Inc mainly meets criteria in the Valuation category. Result from 18 strategies checked.
Pfizer Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
6 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Pfizer Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 21.5 | 30.0 |
| P/B ratio | 1.9 | 4.8 |
| Return on equity (ROE) | 9.0% | 11.5% |
| Equity ratio | 41.5% | 48.4% |
| Debt-to-equity (D/E) | 0.78 | 0.48 |
| Dividend yield | 7.3% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| PFE | Pfizer Incthis page | |
| GILD | Gilead Sciences Inc | High8.2 |
| BMY | Bristol-Myers Squibb Company | High7.3 |
| AMGN | Amgen Inc | Medium5.5 |
| MRK | Merck & Company Inc | locked |
| ABBV | AbbVie Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.